All literature
2021ScienceClinical trial

Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women

Yoshino M. et al.

Longevity

Editor's note

Ten weeks of 250 mg/day NMN in 25 prediabetic women improved insulin-stimulated glucose disposal by 25±7% — comparable to a major weight loss. No effect on body weight, blood pressure, lipids, or hepatic fat. The most-cited piece of human NMN data; small, female-only, single-site.

Read the paperDOI  10.1126/science.abe9985

Related literature

Adjacent reading.

2009Expert Opinion on Biological TherapyReview

From lab to bedside: emerging clinical applications of thymosin alpha 1

Goldstein A.L.

Goldstein's own four-decade overview of thymosin alpha-1 — approved abroad as Zadaxin for hepatitis B/C, sepsis, and as an oncology adjuvant. Useful framing for what the peptide is actually doing immunologically; the US clinical-trial column remains thin.

Longevity

001 — Independent

We don't list what we wouldn't research.

SavePeptides lists vendors after an initial review and distinguishes verified vendors where additional checks have been completed. We may earn commissions from referral links, and sponsored placements will be clearly disclosed.

002 — Vendor-funded

Free to browse. Supported by referrals.

SavePeptides is free for buyers. We may earn a commission when you order through our links, but we do not lock deals behind a paywall, require an email to view codes, or inflate comparison prices.

003 — Research use

Research-use disclaimer.

SavePeptides surfaces vendor, pricing, and coupon information for research compounds. These products are not intended, approved, or recommended for human consumption. Our content is informational only and does not constitute medical advice.